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Summary
 
Mice with a null mutation of the gene encoding interferon consensus sequence–binding pro-
tein (ICSBP) develop a disease with marked expansion of granulocytes and macrophages that
frequently progresses to a fatal blast crisis, thus resembling human chronic myelogenous leuke-
mia (CML). One important feature of CML is decreased responsiveness of myeloid cells to ap-
optotic stimuli. Here we show that myeloid cells from mice deficient in ICSBP exhibit re-
duced spontaneous apoptosis and a significant decrease in sensitivity to apoptosis induced by
DNA damage. In contrast, apoptosis in thymocytes from ICSBP-deficient mice is unaffected.
We also show that overexpression of ICSBP in the human U937 monocytic cell line enhances
the rate of spontaneous apoptosis and the sensitivity to apoptosis induced by etoposide, li-
popolysaccharide plus ATP, or rapamycin. Programmed cell death induced by etoposide was
specifically blocked by peptides inhibitory for the caspase-1 or caspase-3 subfamilies of caspases.
Studies of proapoptotic genes showed that cells overexpressing ICSBP have enhanced expres-
sion of caspase-3 precursor protein. In addition, analyses of antiapoptotic genes showed that
overexpression of ICSBP results in decreased expression of Bcl-X
 
L
 
. These data suggest that
ICSBP modulates survival of myeloid cells by regulating expression of apoptosis-related genes.
Key words: apoptosis • caspase • chronic myelogenous leukemia • interferon • interferon 
consensus sequence–binding protein
 
I
 
nterferon consensus sequence–binding protein (ICSBP)
 
1
 
is a transcription factor of the IFN regulatory factor
(IRF) family (1). Members of the family—IRF-1, -2, -3,
-4, -6, -7, IFN-stimulated gene factor (ISGF)3
 
g
 
, v-IRF,
and ICSBP—are structurally related, bind to the IFN-stim-
ulated response element (ISRE), and regulate expression of
genes stimulated by type I IFN (IFN-
 
a
 
/
 
b
 
) (2–5). Type II
IFN (IFN-
 
g
 
), on the other hand, stimulates transcription of
genes through the IFN-
 
g
 
 activation site (GAS) element
that binds the signal transducer and activator of transcription
(STAT)1, a member of the STAT transcription factor fam-
ily (5, 6). A number of IFN-responsive genes are stimu-
lated by both types of IFN, as there is extensive overlap of
the two transcription pathways (7).
ICSBP was originally identified as a transcription factor
that, similar to IRF-2, acts as a repressor and inhibits IFN-
inducible promoter activities (8). Many attempts have been
made to establish its contributions to IFN signaling, with
recent studies revealing complex roles for this factor in im-
munity, cell cycle regulation, and hematopoiesis (9, 10).
Evidence that IRF family proteins play important roles in
the growth of hematopoietic cells is seen in mice with null
mutations of IRF-1 and IRF-2 (11), which are generally
expressed, as well as IRF-4 (also called PIP or LSIRF) and
ICSBP, which are almost exclusively expressed in hemato-
poietic cells (12). IRF-1
 
2
 
/
 
2
 
 mice have developmental
defects in thymocytes and CD8
 
1
 
 T cell differentiation,
whereas IRF-2
 
2
 
/
 
2
 
 mice exhibit abnormalities of bone
marrow hematopoiesis and B cell development (11). IRF-
4
 
2
 
/
 
2
 
 mice exhibit profound alterations of the function and
homeostasis of both mature B and T cells (12). ICSBP
 
2
 
/
 
2
 
mice are characterized by altered hematopoiesis that mani-
fests as a syndrome similar to human chronic myelogenous
leukemia (CML; reference 10). The most prominent early
features of this disorder are marked expansions of the gran-
ulocytic, monocytic, and, to a lesser extent, lymphoid lin-
 
1
 
Abbreviations used in this paper:
 
 CHX, cycloheximide; CML, chronic my-
elogenous leukemia; FMK, fluoromethyl ketone; ICSBP, interferon con-
sensus sequence–binding protein; IRF, interferon regulatory factor; ISGF,
IFN-stimulated gene factor; ISRE, interferon-stimulated response ele-
ment; RT, reverse transcriptase; STAT, signal transducer and activator of
transcription; TUNEL, TdT-mediated dUTP-biotin nick-end labeling. 
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eages. Older mice experience a transition from this chronic
phase of disease to a clonal, malignant blast crisis (10). A
striking clinical counterpart to myeloid malignancies of
ICSBP
 
2
 
/
 
2
 
 mice comes from the observation that ICSBP
transcripts are greatly decreased in cells of patients with
CML (13).
Human CML is a complex disorder, with enhanced pro-
liferation of granulocyte precursors and reduced sensitivity
of myeloid cells to apoptosis suggested as contributing fac-
tors. A role for IRF family members in regulating cell death
has precedent in the demonstration that DNA damage–
induced apoptosis of peripheral T cells is dependent on IRF-1
(14). Here we show that myeloid cells of ICSBP
 
2
 
/
 
2
 
 mice
have increased resistance to apoptosis, and transfected cells
overexpressing ICSBP have increased sensitivity.
 
Materials and Methods
 
Mice.
 
ICSBP mutant mice were generated as described (10).
Homozygous mutant (
 
2/2
 
) and wild-type (
 
1
 
/
 
1
 
) mice on a
(C57BL/6 
 
3
 
 129/Sv) F
 
2
 
 background were bred and maintained
under specific pathogen-free conditions.
 
Cell Cultures.
 
Single-cell suspensions from spleens, bone mar-
row, and thymi of wild-type and knockout mice were prepared
and resuspended in RPMI 1640 medium (Quality Biological,
Inc.) containing 10% FCS, 15 mM glutamine, 100 U/ml penicil-
lin/streptomycin, nonessential amino acids (GIBCO BRL or
Biofluid, Inc.), and 50 
 
m
 
M 2-ME. For studies of apoptosis, cells
at a concentration of 10
 
6
 
 cells/ml were incubated as 1-ml tripli-
cate aliquots in 24-well plates. U937 human monocytic cells
were stably transfected by electroporation with full length ICSBP
(U937
 
1
 
) or empty vector (pcxn2; U937
 
2
 
) as previously described
(15). Transfectants were maintained in RPMI 1640 medium sup-
plemented with 10% FCS, 2 mM glutamine, 100 U/ml penicil-
lin/streptomycin, and 200 
 
m
 
g/ml G418 (all from GIBCO BRL).
Cells were harvested during exponential growth.
For proliferative responses, single-cell preparations from
spleen, lymph node, and bone marrow were cultured in 96-well
plates at 2 
 
3
 
 10
 
5
 
 cells/ml for 24–72 h. Cells were pulsed with
[
 
3
 
H]thymidine for the last 18 h of culture and assayed for incor-
poration.
 
Induction of Apoptosis.
 
Single-cell suspensions from spleens,
bone marrow, and thymi of ICSBP
 
2
 
/
 
2
 
 mice and ICSBP
 
1
 
/
 
1
 
 lit-
termates were isolated and cultured with 10 
 
m
 
g/ml etoposide
(Sigma Chemical Co.) or 30 ng/ml TNF-
 
a
 
 (R & D Systems,
Inc.) plus 10 
 
m
 
g/ml cycloheximide (CHX; Sigma Chemical
Co.). After 18 h, cells were stained and TUNEL (TdT-mediated
dUTP-biotin nick-end labeling) assay and flow cytometric analy-
ses were performed.
U937
 
1
 
 and U937
 
2
 
 transfectants were washed and cultured for
24 h at a concentration of 3 
 
3
 
 10
 
5
 
 cells/ml in serum-free RPMI
1640 medium supplemented with 500 U/liter insulin (Eli Lilly
and Co.) and 5 mg/liter transferrin (GIBCO BRL). Cells were
treated with 20 
 
m
 
g/ml etoposide or 30 ng/ml TNF-
 
a
 
 plus 10
 
m
 
g/ml CHX, incubated for 18 h, and then harvested and assayed
for apoptosis. In some experiments, transfectants were treated
with 1 
 
m
 
g/ml LPS (Sigma Chemical Co.) for 4 h and then with 2
mg/ml ATP (Sigma Chemical Co.) for 30 min, incubated for 6 h,
and then harvested and assayed for apoptosis. For protease inhibi-
tion experiments, cysteine protease inhibitors ZVAD-fluoro-
methyl ketone (FMK), BD-FMK, and the control ZFA-FMK re-
agent (provided by Dr. P.A. Henkart, National Cancer Institute,
Bethesda, MD) were added at a concentration of 50 
 
m
 
M 1 h be-
fore induction of apoptosis.
 
TUNEL Assay.
 
The presence of DNA nicking in apoptotic
cells was assayed, with minor modifications, according to Gor-
czyca et al. (16). In brief, cell samples were collected and fixed in
1% formaldehyde in PBS on ice, washed once with PBS, resus-
 
Table I.
 
Sequences of PCR Primers
 
Gene Primers Probe
 
Caspase-2
 
Sense 5
 
9
 
-GTTACCTGCACACCGAGTCACG-3
 
9
 
5
 
9
 
-TGACAACGCCAACTGCCCAAGCCT-3
 
9
 
Antisense 5
 
9
 
-AGGGGATCCTGCGCGTGGTTCTTATC-3
 
9
 
Caspase-3
 
Sense 5
 
9
 
-CTGCCTCTTCCCCCATTCTC-3
 
9
 
5
 
9
 
-GGAAGCGAATCAATGGACTC-3
 
9
 
Antisense 5
 
9
 
-CTTGTCGGCATACTGTTTCA-3
 
9
 
Caspase-1
 
Sense 5
 
9
 
-TGATTGACTCCGTTATTCC-3
 
9
 
5
 
9
 
-ACAATGCTGCTACAAAATC-3
 
9
 
Antisense 5
 
9
 
-CTTCTCTATGTGGGCTTTC-3
 
9
 
Caspase-7
 
Sense 5
 
9
 
-CGAAACGGAACAGACAAAGAT-3
 
9
 
5
 
9
 
-TTATGGGAAAGATGGTGTCACA-3
 
9
 
Antisense 5
 
9
 
-TGGAATAGGCGAAGAGGAGGAAGT-3
 
9
 
Bcl-X
 
L
 
Sense 5
 
9
 
-CAGTGAGTGAGCAGGTGTTTTG-3
 
9
 
5
 
9
 
-GGCGGCTGGGATACTTTTGTGG-3
 
9
 
Antisense 5
 
9
 
-AGGGGGTGGGAGGGTAGAGTGG-3
 
9
 
MCL-1
 
Sense 5
 
9
 
-CCGCTTGAGGAGATGGAA-3
 
9
 
5
 
9
 
-CGACGCCGCCGCCAGCAG-3
 
9
 
Antisense 5
 
9
 
-ACGCCGTCGCTGAAAACA-3
 
9
 
cIAP2
 
Sense 5
 
9
 
-TACTCCAGCCTTCCTCCAAACC-3
 
9
 
5
 
9
 
-GCCTGCTTTGCCTGTGGTGGGA-3
 
9
 
Antisense 5
 
9
 
-CTCCAGATTCCCAACACCTCAA-3
 
9
b
 
2
 
m Sense 5
 
9
 
-AGCGTACTCCAAAGATTCA-3
 
9
 
5
 
9
 
-GAGTATGCCTGCCGTGTGA-3
 
9
 
Antisense 5
 
9
 
-CTACCTGTGGAGCAACCTG-3
 
9
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pended in cold 70% ethanol in PBS, and stored at 2208C. After
rehydration, cells were resuspended in cacodylate buffer, 25 mM
CoCl2, and 0.5 nM biotin-dUTP in the presence or absence of
10 U TdT enzyme (Boehringer Mannheim Biochemicals) and
incubated at 378C. After washing in PBS, cells were resuspended
in saline citrate buffer containing 43 SSC, 2.5 mg/ml FITC–avi-
din (Boehringer Mannheim Biochemicals), 0.1% Triton X-100
(Sigma Chemical Co.), and 5% nonfat dry milk. After a 30-min
incubation in the dark, cells were washed in PBS with 0.1% Tri-
ton X-100 and 0.5% BSA and resuspended in Sorter medium
(Quality Biological, Inc.). dUTP incorporation by individual
cells was measured by green fluorescence on a FACScan™ flow
cytometer using Cellquest™ data software (Becton Dickinson).
Flow Cytometric Analysis and DNA Labeling. Cells were stained
with FITC-labeled Abs, including those to CD4, CD8, B220,
Mac-1, and 8C5 (GR-1; all from PharMingen). In brief, cells
were resuspended in 100 ml PBS containing 2% FCS and incu-
bated with various mAbs (1 mg/ml) for 20 min. After one wash
with PBS, cells were stained for TUNEL assay. Analysis was per-
formed on a FACScan™ flow cytometer.
Reverse Transcriptase PCR.  mRNA was isolated using RNA-
zol (Tel-Test) followed by extraction with chloroform and iso-
propanol. 1 mg of RNA was transcribed using MMLV-H(2) re-
verse transcriptase (RT; Promega Corp.) and then amplified by
PCR using primers described in Table I under the following
conditions: 13 reaction buffer (Promega Corp.), 2.5 mM MgCl2,
2.5 mM dNTP, 5 mM of each primer, and 1 U of Taq DNA
polymerase (Promega Corp.) in a total volume of 40 ml. Amplifi-
cation was carried out through 30 cycles. PCR products were
separated on 1.2% agarose gels and analyzed by Southern blot hy-
bridization with FITC-labeled probes using an ECL-39 oligola-
beling and detection system and Hyperfilm-ECL (Amersham In-
ternational).
Western Blot Analysis. Whole cell extracts were prepared by
lysing cells for 30 min at 48C with lysis buffer (50 mM Tris, pH
7.5, 2 mM EDTA, 100 mM NaCl, 1 mM Na3VO4, 1% NP-40,
10 mg/ml leupeptin, 5 mg/ml aprotinin, and 10 mg/ml PMSF) at
a concentration of 106 cells/50 ml. After centrifugation at 48C for
15 min, aliquots of the extracts containing 100 mg of protein
were subjected to 10% SDS-PAGE. The proteins were then elec-
trophoretically transferred to PVDF (polyvinylidine difluoride)
membrane filters (Bio-Rad Labs.). Filters were probed with sc-
515, a rabbit polyclonal Ab to human caspase-1; sc-625, a rabbit
polyclonal Ab to caspase-2 of human origin; sc-1224, a goat
polyclonal Ab to human caspase-3; sc-1041, a rabbit polyclonal
Ab to human Bcl-XS/L; or an Ab to p53 (all from Santa Cruz
Biotechnology, Inc.) at a concentration of 1 mg/ml in PBS with
5% dried milk and 0.2% Tween 20. Detection was carried out with
secondary horseradish peroxidase–linked anti–rabbit or anti–goat
Abs (Amersham International) and the Amersham ECL system.
Transient Transfection and Luciferase Assay. Primers correspond-
ing to the human Bcl-XL promoter at positions 77–101 (AAGT-
CAGATTGCAGATCTGAGGCAG) and positions 745–769
(GAATTCACTTCATAGAACCTTGGAT) as previously re-
ported (17; sequence available from EMBL/GenBank/DDBJ un-
der accession number D30746) were used in a genomic PCR re-
action to obtain the Bcl-XL promoter region. The PCR product
was cloned into a basic pGL3 luciferase vector (Promega Corp.)
cut with SacI and HindIII. The resulting plasmid was prepared by
the CsCl gradient method as previously reported (18) and used
for transient transfection assays. RAW cells, a mouse macrophage
tumor line, were transfected by electroporation using the Cell-
Porator (GIBCO BRL). In brief, up to 30 mg of plasmid DNA
was mixed with 1.0 3 107 cells/ml and resuspended in 0.4 ml of
fresh complete RPMI 1640 medium containing 10% FCS. The
cell/DNA mixture was then incubated on ice for 10 min before
electrical shock at 300 mV and 800 mF. Cells were then trans-
ferred into 10 ml of fresh medium and left at room temperature
for 10 min before incubation at 378C. 24 h after transfection, lu-
ciferase assays were performed as reported (19).
Results
Apoptosis Is Decreased in Myeloid Cells from ICSBP2/2
Mice. Although it was initially assumed that CML is
caused by uncontrolled cell proliferation resulting in the
clonal expansion evident in this disease, some studies have
indicated that the rates of proliferation are not significantly
increased (20, 21). Other studies have shown that myeloid
cells of CML patients have increased resistance to apopto-
sis, indicating that this disease may result from suppression
of cell death rather than ungoverned proliferation (22, 23).
To investigate the possible relatedness of the disease of
ICSBP2/2 mice to CML, we first studied the levels of
spontaneous proliferation and apoptosis of cells from nor-
Figure 1. Spontaneous proliferation and apoptosis in cells of ICSBP2/2
mice. (A) Cells were cultured for 24–72 h and pulsed with [3H]thymidine
for the last 18 h of culture. (B) Cells from 2/2 mice and 1/1 litter-
mates were cultured for 1 and 2 d and analyzed for apoptosis by TUNEL
assay. Data are representative of three experiments using 10–16-wk-old
mice.414 ICSBP Regulation of Apoptosis in Myeloid Cells
mal and mutant mice. As shown in Fig. 1 A, the prolifera-
tion of cultured spleen, lymph node, and bone marrow
cells of mutant mice was increased over normal when as-
sayed at 24–72 h. To examine whether reduced pro-
grammed cell death might contribute to the expansion of
myeloid cells in ICSBP2/2 mice, we examined spontane-
ous apoptosis of cultured cells from spleen, thymus, and
bone marrow by TUNEL assay (Fig. 1 B). These studies
revealed a significant reduction in the level of apoptotic
death exhibited by spleen and bone marrow cells from
ICSBP2/2 mice. In contrast, thymocytes from ICSBP2/2
and ICSBP1/1 mice behaved similarly. To determine
whether specific cell populations accounted for the reduced
rate of apoptosis in spleen and bone marrow, cells were as-
sayed simultaneously for apoptosis and expression of cell
lineage markers. Mac-11 and, to a lesser extent, GR-11
cells from spleen and bone marrow of ICSBP2/2 mice ex-
hibited a significant reduction in the rate of apoptosis (Fig.
2, untreated cells). In contrast, the rates of apoptosis were
comparable among CD41/CD81 and B2201 cells from
mice of either genotype.
To further investigate the possible role of ICSBP in apop-
tosis of myeloid cells, we examined programmed cell death
induced by etoposide, an agent that induces DNA breaks
by inhibiting the religation activity of topoisomerase II. As
shown in Fig. 2, apoptosis induced by etoposide was signif-
icantly reduced in GR-11 and Mac-11 cells from spleens
and bone marrow of ICSBP2/2 mice. In contrast, apoptosis
of splenic B and T cells was not affected. Interestingly,
bone marrow T cells from ICSBP2/2 mice were signifi-
cantly more sensitive to etoposide than were cells from het-
erozygotes. Finally, we tested cells from ICSBP2/2 and
ICSBP1/1 mice for their sensitivity to apoptosis induced by
TNF-a plus CHX. No differences in responsiveness were
noted for cells of any phenotype for either genotype (Fig.
2). These findings indicate that ICSBP selectively affects
distinct pathways leading to apoptosis of myeloid cells: in-
duction by etoposide is clearly modulated by ICSBP,
whereas the pathway activated by TNF-a plus CHX is not.
Apoptosis Is Enhanced in U937 Cells Overexpressing
ICSBP. A full length ICSBP construct was stably trans-
fected into U937 human monocytic cells (U9371), result-
ing in levels of ICSBP proteins that were z10–30-fold
higher than endogenous ICSBP (15). Transfectants con-
taining the vector without insert (U9372) were used as
controls. For these studies, three clones of each transfectant
were selected and pooled. Using the TUNEL assay for de-
tection of DNA strand breaks, we examined apoptosis of
both cell populations cultured in serum-free medium sup-
plemented with insulin and transferrin. During the first 18 h
of culture, neither U9371 nor U9372 cells showed clear
evidence of apoptosis, but prominent differences were seen
at 38 and 68 h (Fig. 3), indicating a proapoptotic role for
ICSBP in myeloid cells.
Apoptosis is controlled by many distinct signals (24, 25),
but it appears that different signaling pathways ultimately
converge to activate a common program (26). It has been
shown that U937 cells undergo apoptosis in response to
multiple agents (27, 28). To further investigate the function
of ICSBP in the regulation of distinct apoptotic pathways,
we treated U9371 and U9372 cells with different apopto-
sis-inducing agents. U9371 cells exhibited greater suscepti-
bility to DNA damage–induced death than did control
cells. After 10 h of treatment with etoposide, almost 70%
of U9371 cells were TUNEL positive, in contrast to 30%
of control cells (Fig. 4). Interestingly, apoptosis was in-
duced by TNF-a plus CHX at the same levels in U9372
and U9371 cells (data not shown), suggesting again that
ICSBP is involved only in specific pathways of pro-
grammed cell death. A moderately enhanced sensitivity to
apoptosis was also observed in U9371 cells after treatment
with LPS plus ATP. It was shown previously that ATP
Figure 2. Macrophages and gran-
ulocytes account for reduced levels
of apoptosis in spleen and bone
marrow cells of ICSBP2/2 mice.
Cells from ICSBP2/2 mice and
ICSBP1/1 littermates were cultured
for 18 h alone, with etoposide (10
mg/ml), or with TNF-a (30 ng/ml)
plus CHX (10 mg/ml), stained with
the indicated Ab, and fixed for
TUNEL assays. Data are represen-
tative of three experiments using
10–16-wk-old mice.415 Gabriele et al.
treatment leads to apoptosis via a caspase-1–independent
pathway (29). We found that treatment with LPS for 4 h
and then with ATP for 30 min induced apoptosis in 60%
of U9371 cells but only 45% of U9372 cells (Fig. 4).
Moreover, U9371 cells were significantly more sensitive to
rapamycin, a potent immunosuppressive drug that has been
shown to interfere with growth factor–induced cell prolif-
eration and induce apoptosis in a murine B cell line (30)
(data not shown). Although to date there is no direct evi-
dence for the involvement of ICSBP in cell growth path-
ways, our results clearly show that ICSBP plays a role in
the apoptotic response of U937 cells to specific death-
inducing signals and confirm that ICSBP itself might con-
tribute to spontaneous and DNA damage–induced apopto-
sis in this system.
Inhibition of Etoposide-induced Apoptosis by ZVAD-FMK
and BD-FMK in U9371 Cells. We next examined the
role of caspases in programmed cell death of U9371 cells. It
is evident that caspases are important effector molecules of
apoptosis (26, 31). To determine whether specific caspase
subfamilies contribute to apoptosis in U9371 cells treated
with etoposide, we tested the activity of two cell-perme-
able peptide FMK inhibitors of caspase-1 (IL-1b convert-
ing enzyme-family) proteases (32). ZVAD-FMK specifi-
cally blocks the caspase-1–like subfamily, and BD-FMK
preferentially inhibits caspase-3–like proteases. ZFA-FMK,
which lacks inhibitory activity for caspases, was used as a
negative control. Both ZVAD-FMK and BD-FMK inhib-
ited apoptotic death induced by etoposide in U9371 (Fig.
5) and U9372 cells (data not shown). These results suggest
that ICSBP enhances the sensitivity of U937 monocytic
cells to apoptosis induced by etoposide and that the apop-
totic process involves the activity of members of the
caspase-1 and caspase-3 subfamilies.
Control of Caspase Gene Expression by ICSBP. To ad-
dress the possibility that ICSBP may interfere with the acti-
vation of caspases, we examined the expression of cas-
pase-1, -2, -3, and -7 (33–36). Semiquantitative RT-PCR
was performed on each cell population before and after
treatment with etoposide (Fig. 6, left). Transcripts for
caspase-2 and -3 were present at similar levels before and
after treatment of U9371 and control cells. In contrast,
caspase-7 and, to a lesser extent, caspase-1 transcripts were
increased in U9371 before and after induction of apoptosis
with etoposide. b2 microglobulin transcripts, run as a con-
trol, were comparable in both clones. These results suggest
Figure 3. U937 cells overex-
pressing ICSBP show increased
spontaneous apoptosis. U9371
and U9372 cells were cultured
for the indicated times and as-
sayed for apoptosis by TUNEL.
Data are representative of three
independent experiments.
Figure 4. Apoptosis induced by etoposide or LPS plus ATP is en-
hanced in U937 cells overexpressing ICSBP. Cells were treated with re-
agents as indicated in Materials and Methods and assayed for apoptosis by
TUNEL. Data are representative of three or more experiments. Solid
bars, untreated cells; hatched bars, treated cells.
Figure 5. Caspase inhibitors block apoptosis in cells overexpressing
ICSBP. Cells were incubated with caspase inhibitors ZVAD-FMK and
BD-FMK and the inactive reagent ZFA-FMK for 1 h before addition of
etoposide. TUNEL assays were performed 16 h later. Data are representa-
tive of three experiments.416 ICSBP Regulation of Apoptosis in Myeloid Cells
that overexpression of ICSBP in U937 cells may affect apop-
tosis by enhancing expression of the proapoptotic genes of
caspase-1 and -7.
This study was extended by Western blot analysis.
Whole cell lysates were prepared from U9371 and U9372
cells before and after treatment with etoposide, and immu-
noblot analysis was performed. The 48-kD precursor pro-
tein of caspase-2 was detectable before treatment in both
cell types (Fig. 6, right), whereas two smaller fragments
were generated from the cleavage of the caspase-2 precur-
sor after treatment with etoposide. Notably, the strength of
the low-molecular-mass fragments correlated with the in-
creased sensitivity of U9371 cells to etoposide.
We next examined the expression of caspase-3 precursor
protein. The most striking finding was markedly increased
levels of the precursor in U9371 cells. After treatment with
etoposide, the precursor was processed to generate a lower-
molecular-mass fragment, reflecting induction of apoptosis.
Although our previous results showed that expression of
caspase-3 mRNA was not altered in ICSBP clones, West-
ern blot analysis revealed a markedly enhanced expression
of caspase-3 protein. These data suggest that ICSBP might
control caspase-3 activity through modulation of transla-
tion or protein stability rather than transcription. In light of
enhanced caspase-1 mRNA expression in U9371 cells, it
was of interest to determine whether caspase-1 protein ex-
pression was also affected. We found the 45-kD precursor
of caspase-1 was slightly overexpressed in U9371 cells. Be-
cause U9371 cells show enhanced sensitivity to apoptosis
induced by ATP via a caspase-1–independent pathway
(29), these new findings suggest that increased expression of
caspase-1 is unlikely to be the basis for this phenotype. It
thus seems that caspase-3 plays a major role in cell death
signaling pathways controlled by ICSBP.
Bcl-XL Expression Is Reduced in U9371 Cells. We next
asked whether ISRE-binding activities could control ex-
pression of antiapoptotic genes. Using semiquantitative
RT-PCR analysis, we examined expression of members of
the Bcl-2 family, including Bcl-XL, Bcl-2, and Mcl-1 (37),
as well as the proapoptotic gene, Bax (38). Bcl-XL tran-
scripts were decreased by z50% in U9371 cells (Fig. 7 A),
whereas the levels of Bcl-2, Mcl-1, and Bax transcripts
were comparable (data not shown). Treatment with etopo-
side resulted in downregulation of Bcl-XL expression in
both cell types. Because U9371 and U9372 cells were
equally sensitive to TNF plus CHX and U9371 cells were
much more sensitive to etoposide, the importance of
changes in Bcl-XL expression induced by ICSBP may con-
tribute to changes in only some pathways of programmed
cell death. The reduced levels of Bcl-XL transcripts ob-
served in U9371 cells suggested that IFN might have a pre-
viously unappreciated role in regulating expression of this
gene. We therefore examined levels of Bcl-XL protein in
U9372 cells stimulated with IFN-a or IFN-g. Both cyto-
kines induced significant increases in Bcl-XL expression
that were maximal at 12 h of treatment (Fig. 7 B).
To further examine ICSBP regulation of Bcl-XL, we
tested Bcl-XL promoter activity in RAW cells, a mouse
Figure 6. Caspase expression is modulated in cells overexpressing
ICSBP. U9372 and U9371 cells were treated to induce apoptosis with
the indicated reagents. Left, RT-PCR analyses of transcripts for the indi-
cated genes. Right, Western blot analysis of caspase expression. Data are
representative of three experiments.
Figure 7. Regulation of Bcl-XL expression. (A) RT-PCR analyses of
Bcl-XL transcripts in untreated cells and cells treated for 18 h with TNF-a
plus CHX or with etoposide. (B) Western blot analyses of Bcl-XL levels
in U9372 cells stimulated for the indicated times with IFN-a or IFN-g.
(C) Luciferase assays of Bcl-XL promoter activity in RAW cells. Cells
were transfected with vector either alone or with IRF-1, IRF-2, or
ICSBP. Data are representative of two experiments.417 Gabriele et al.
macrophage tumor line, using a transient transfection assay.
As shown in Fig. 7 C, luciferase activity driven by a 645-bp
Bcl-XL promoter was significantly reduced by ICSBP but was
not significantly affected by cotransfection of IRF-1 or IRF-2.
As a control, RSV (Rous sarcoma virus) promoter activity
was also unaffected, indicating specificity of the effect and
suggesting that ICSBP represses transcription of Bcl-XL.
Finally, we examined the expression of the antionco-
genic transcription factor p53, which has been shown to be
required to induce cell death in oncogene-expressing cells
that have suffered DNA damage (39). p53 protein levels
were significantly increased in U9371 cells (Fig. 8), sug-
gesting another mechanism by which ICSBP might be in-
volved in the induction of spontaneous apoptosis and the
DNA damage response pathway.
Discussion
It is widely recognized that myeloid cells die via apopto-
sis (40), but the mechanisms involved in determining apop-
totic death in this lineage have only recently come to be
partially understood (41, 42). ICSBP knockout mice ex-
hibit dysregulated hematopoiesis, defining a role for ICSBP
in the proliferation and differentiation of hematopoietic
cells. Here we report that myeloid cells from ICSBP-defi-
cient mice exhibited reduced spontaneous apoptosis and a
significant decrease in sensitivity to apoptosis induced by
DNA damage. Moreover, overexpression of ICSBP in
U937 cells was sufficient to enhance their sensitivity to
spontaneous and induced apoptosis. Our results thus define
ICSBP as a regulator of myeloid cell survival. We also
point out that ICSBP is likely to normally function in reg-
ulation of the cell cycle in hematopoietic cells, because the
spontaneous proliferation of bone marrow, spleen, and
lymph node cells from mutant mice was significantly in-
creased.
ICSBP has been identified as a negative transcription fac-
tor that binds to ISREs found in the promoters of type I
IFNs and IFN-inducible genes (43, 44). Unlike IRF-1,
IRF-3, and ISGF3g, ICSBP exhibits a tissue-restricted pat-
tern of expression largely limited to cells of the immune
system, particularly the monocytic and lymphoid lineages.
Expression of ICSBP is constitutive and can be dramatically
enhanced by IFN-g. The intrinsically weak DNA binding
affinity of ICSBP (45) is dramatically increased after het-
erodimerization with IRF-1 or IRF-2 (3, 46). ICSBP/
IRF-2 binding to DNA is constitutive, whereas ICSBP/
IRF-1 DNA binding is only induced by IFN-g. Several
studies implicate IRF-1 as a critical tumor suppressor, regu-
lating oncogene-induced cell transformation or apoptosis
(39, 47). It has been reported that IRF-1 regulates DNA
damage–induced apoptosis in mitogen-activated peripheral
T cells (14). IRF-1 is also required for the induction of ap-
optosis in fibroblasts carrying an activated c-Ha-ras gene af-
ter DNA damage or culture in low serum (39). Moreover,
IRF-1 has been implicated in IFN-g–induced apoptosis of
hematopoietic progenitor cells (48). Our data provide evi-
dence that ICSBP, another member of the IRF family, can
regulate apoptosis of myeloid cells.
ICSBP2/2 mice exhibit expanded populations of granu-
locytic, monocytic, lymphoid, and perhaps megakaryocytic
lineages (10), suggesting that the decisive alteration occurs
in an early common progenitor cell. Our studies revealed
that the sensitivity to apoptosis of Mac-11 and GR-11 cells
from spleen and bone marrow of ICSBP2/2 mice was sig-
nificantly reduced. Expression of these markers is different
in myeloid subpopulations; granulocytes are GR-11Mac-11
or GR-11Mac-12, and macrophages are GR-12Mac-11
(49), indicating that both macrophages and granulocytes
from ICSBP2/2 mice exhibited impaired programmed cell
death. In contrast, the rate of apoptosis was comparable in
T and B cells from 1/1 or 2/2 mice, suggesting a spe-
cific role for ICSBP in apoptosis in the myeloid lineage.
Analysis of apoptosis induced by etoposide confirmed the
specific proapoptotic role of ICSBP in myeloid cells. GR-11
and Mac-11 cells from spleen and bone marrow of
ICSBP2/2 mice showed a significantly reduced sensitivity
to apoptosis induced by this DNA-damaging agent. In
contrast, etoposide-induced apoptosis of B and T cells from
ICSBP2/2 and wild-type mice was similar.
We also found that the proliferation index of bone mar-
row, spleen, and lymph node cells of ICSBP2/2 mice was
increased over normal. This suggests that the early accumu-
lation of hematopoietic cells that characterizes these animals
is mediated by enhanced proliferation as well as by reduced
apoptosis. Studies of U937 cells overexpressing ICSBP
provided strong support for the proposed role of ICSBP in
regulating apoptosis in myeloid cells. ICSBP expressed at
levels 10–30-fold higher than endogenous levels sensitized
cells to spontaneous apoptosis and selective pathways of re-
sponse to exogenous stimuli. U9371 cells exhibited greater
sensitivity to apoptosis induced by DNA damage, treat-
ment with LPS plus ATP, and inhibition of TOR/FRAP
kinase by rapamycin (reference 50; data not shown), but
not to treatment with TNF-a plus CHX. This suggests
that apoptotic pathways initiated by engagement of death
receptors leading to rapid activation of caspase cascades are
insensitive to effects mediated by ICSBP, whereas other
pathways are sensitive. This pattern of sensitivity and resis-
tance to the effects of ICSBP is similar to that suggested for
Bcl-2 and Bcl-XL: little or no effect on apoptosis induced
by death receptor engagement but prominent regulation of
apoptosis induced by growth factor withdrawal or DNA
damage (51–53). It is unclear whether these selective effects
on apoptosis are mediated by ICSBP alone or in combina-
tion with other IRF family members. IRF-1 is an impor-
tant requirement of DNA damage–induced apoptosis of
peripheral T cells (14) but not myeloid cells, at least on its
own, because it is expressed at normal levels in ICSBP2/2
mice.
Figure 8. Western blot analyses of
p53 expression in U9372 and
U9371 cells.418 ICSBP Regulation of Apoptosis in Myeloid Cells
Inhibition of TOR/FRAP by rapamycin (53) leads to
G1 arrest in some systems (54) and acceleration of apoptosis
in others (55). The results of TOR activation—either
growth arrest or apoptosis—resemble the pattern of re-
sponses to p53 activation (56). Because p53 expression is
enhanced in U9371 cells, ICSBP may regulate apoptosis by
acting as a rheostat to balance the activities of these bifunc-
tional genes. Induction of apoptosis by p53 in some systems
is thought to involve transcriptional induction of Bax (57).
This activity is unlikely to be relevant to our system, be-
cause Bax transcripts were similar in control and U9371
cells. The importance of TOR to apoptosis could reflect its
regulation by Akt, which functions in the phosphatidyl-
inositol-3 kinase pathway to inhibit apoptosis (58). Inhibi-
tion of TOR may induce apoptosis by inactivating down-
stream signaling pathways that involve p70S6K kinase or
4E-BP-1 (59).
Further analysis of U9371 cells revealed that ICSBP may
affect expression of caspases involved in the central control
and execution stages of cell death (60–63). Our results re-
vealed that transcripts for caspase-2 and -3 were expressed
at the same level in U9372 and U9371 cells before and af-
ter induction of apoptosis with etoposide. In contrast,
caspase-7 and, to a lesser extent, caspase-1 transcripts were
increased before and after induction of apoptosis of U9371
cells with etoposide. These data show that expression of
caspases belonging to distinct subfamilies is differentially
regulated by ICSBP.
Our studies also revealed that caspase protein expression
is specifically modulated in U9371 cells. First, activation of
caspase-2 was enhanced in U9371 cells. Second, although
caspase-3 transcripts were not increased in cells overex-
pressing ICSBP, levels of the caspase-3 precursor protein
were significantly increased. Finally, caspase-1 precursor
levels were higher in U9371 than in control cells before
and after induction of apoptosis with etoposide. These re-
sults clearly show that increased expression of caspase-1, -3,
and -7 occurred in U9371 cells in association with en-
hanced sensitivity to spontaneous and induced apoptosis.
Although we have no direct evidence at present for the
transcriptional or translational control of caspases by
ICSBP, the enhanced levels of one or more could account
for the priming of a cascade that leads to the effector phases
of apoptosis.
Cell death is regulated by a number of genes that influ-
ence cell survival in either a positive or negative fashion.
The Bcl-2 family consists of molecules that can either pro-
mote survival or augment programmed cell death (64, 65).
The capability of type I and type II IFNs to modulate the
expression of genes belonging to the Bcl-2 family is a con-
troversial issue (66, 67). Recent reports revealed that IFN-g
significantly inhibits eosinophil apoptosis but does not up-
regulate Bcl-2 expression (68). In addition, IFN-a2 is re-
ported to inhibit the growth of myeloma cells in a manner
independent of Bcl-2 and Bcl-XL expression (69). On the
other hand, a recent report has shown that leukemia inhib-
itory factor induces Bcl-XL mRNA via a STAT1-binding
cis-element in cardiac myocytes, preventing a cytoprotec-
tive effect (70). We found that U9371 cells exhibited a spe-
cific decrease in Bcl-XL transcripts. Moreover, our data
show that Bcl-XL can be strongly induced by IFN-a and
IFN-g. Finally, our results clearly demonstrate that a con-
sensus ISRE present in the promoter region of Bcl-XL is
sufficient to confer efficient IFN-a inducibility. Surpris-
ingly, Bcl-2 expression was not affected in U9371 cells.
These results argue for a Bcl-2–independent but Bcl-XL–
dependent mechanism of apoptosis regulation by ICSBP.
In our model, downregulation of Bcl-XL could promote
caspase-1–dependent disruption of the mitochondrial inner
transmembrane potential and the subsequent activation of
caspase-3 and -7. Recently, posttranscriptional modifica-
tions of some Bcl-2 family members have been shown to
regulate cell death (71, 72). Because Bcl-XL by itself is able
to form ion channels in membranes (73) and is present in
both soluble and membrane-bound forms, it would be in-
teresting to determine whether mRNA expression, post-
transcriptional modifications, and/or subcellular localiza-
tion of this antiapoptotic protein represent important steps
in the pathway by which IRF family members regulate cell
death. Furthermore, because the functional relationship be-
tween the Bcl-2 family of apoptotic modulators and the
caspases remains unresolved, our model might be useful for
elucidating specific interactions between these families of
proteins.
Although the precise mechanism by which ICSBP mod-
ulates expression of genes involved in apoptosis remains to
be elucidated, our data argue for a specific proapoptotic ac-
tivity elicited in U937 cells overexpressing ICSBP. In addi-
tion, studies of ICSBP-deficient mice strongly support the
involvement of this factor as a regulator in the apoptotic
pathway of myeloid cells whose leukemic transformation
might follow escape from normal apoptotic controls; how-
ever, the possible relations between the myeloid disease of
ICSBP mice and human CML remain to be clearly de-
fined. We also found that the proliferative rate of bone
marrow cells from ICSBP2/2 mice was increased, suggest-
ing that enhanced proliferation as well as prolonged sur-
vival may contribute to this myeloid disorder.
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